Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
This Phase I open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
no clinically significant diseases or clinically significant abnormal laboratory values
females must be of non-childbearing potential
body mass index (BMI) is \>/=18 kg and ≤30 kg/m2
nonsmoker
negative drug screen
You may not be if
positive test results for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
any clinically relevant abnormality
female subject is pregnant or breast-feeding
history of any anaphylactic reaction to any drug
history of significant cardiovascular or pulmonary dysfunction
current or chronic history of liver disease
history of alcohol or substance abuse
history of thyroid dysfunction or disease
history of gastrointestinal surgery or disease
history of pancreatitis
previously received any GLP-1 mimetic compound (e.g., exenatide)
